COVID-19 preclinical drug development database
Dose selection of therapeutics targeting COVID-19 using the hollow fibre infection model
University of Liverpool
Added 15/05/2020 | Updated 04/10/2021
Project Details
Type of project
- Tier 2: testing existing molecules
- Tier 3: discovering and categorising new molecules
- Supporting technologies, models and assays
Therapeutic target
- Direct acting antiviral
Type of supporting technology
- In vitro hollow fibre infection model system for SARS-Cov-2
Phase of project
- PK/PD testing and toxicology
Modality (if can be disclosed)*
- Small molecule
Molecular/cellular target (if known or can be disclosed)*
- Not known
- Not disclosed
Partner institutions/organisations
- Liverpool School of Tropical Medicine
Key contact
Name: Shampa Das
Email Address: shampa.das@liverpool.ac.uk
Phone Number:
Key Collaborators:
Anticipated timeframe of future outputs
12+ months
Further Details
Abstract or additional information (if available)*
Novel approaches are urgently required to establish effective clinical regimens for SARSCov- 2. Pharmacokinetics-pharmacodynamics (PK-PD) provides the tools to ensure the optimal dosing required is used. Hollow fibre infection models (HFIM) are widely used in antimicrobial drug development. Currently, there are no HFIM models of SARS-CoV-2 and no way to quickly identify regimens for new or repurposed antivirals.
Published outputs (if available)*
Relevant weblinks
Similar Projects
Project Name
Lead institution
